FibroGen

K. Peony Yu, M.D., has been named vice president, clinical development at FibroGen. Dr. Yu has expertise in design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the U.S. and EU, as well as experience with successful leadership of clinical teams.

Dr. Yu was most recently vice president, clinical research, at Anesiva, Inc., where she was responsible for management of clinical research, statistics/data management, clinical operations, and medical affairs/medical information for all clinical programs, including the late-stage clinical development and approval of Zingo, a drug-device combination for pain management. Prior to Anesiva, Dr. Yu was director, clinical development, at ALZA Corp. (a subsidiary of Johnson & Johnson) where she was global clinical lead for IONSYS, a drug-device combination for post-operative pain, and led a successful NDA resubmission with the FDA and multiple interactions with European regulatory authorities resulting in marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held previous posts at Pain Therapeutics, Inc. and Elan Pharmaceuticals.

“Peony’s experience in leading multifunctional clinical teams with proven success in advancing investigational products through all stages of clinical development through regulatory approval will be an important asset to FibroGen,” said Frank H. Valone, M.D., chief medical officer of FibroGen. “We look forward to her leadership of our multiple clinical programs in the U.S. and globally.”